PRC-2 epigenetic chromatin reprogramming in ALK-positive (ALK+) lung cancer initial emergence of precision drug resistance.

12020Background: Despite remarkable upfront response to ALK tyrosine kinase inhibitors (TKIs) in ALK+ lung cancer, acquired resistance eventually develops. Molecular mechanisms of the initial emerg...